Editorial: Treatment of cancer

December 1973
British Medical Journal;12/1/1973, Vol. 4 Issue 5891, p503
Academic Journal
No abstract available.


Related Articles

  • Smoking, treatment for Hodgkin's Disease, and subsequent lung cancer risk. Boivin, Jean-Francois // JNCI: Journal of the National Cancer Institute;10/18/95, Vol. 87 Issue 20, p1502 

    Editorial. Studies the effect of treatment of Hodgkin's disease and of smoking on subsequent lung cancer risk. Factors that increase lung cancer risk.

  • Lung epithelial proliferation: a biomarker for chemoprevention trials? Szabo, Eva; Szabo, E // JNCI: Journal of the National Cancer Institute;7/18/2001, Vol. 93 Issue 14, p1042 

    Editorial. Focuses on the molecular pathogenesis of lung cancer. Causes of cancer death; Treatment of advanced malignancy; Performance of tamoxifen in reducing breast cancer risk.

  • EDITORIALS. Morris Jr., J. Glenn; Morrow Jr., K. John // Annals of Internal Medicine;8/15/88, Vol. 109 Issue 4, p261 

    Editorial. Discusses different topics on internal medicine. Clinical and epidemiologic features of Vibrio vulnificus; Significance of monoclonal antibodies for cancer treatment.

  • Ribozymes as therapeutic agents: are we getting closer? Scanlon, Kevin J.; Kashani-Sabet, Mohammed; Scanlon, K J; Kashani-Sabet, M // JNCI: Journal of the National Cancer Institute;04/15/98, Vol. 90 Issue 8, p558 

    Editorial. Discusses the use of ribozymes as therapeutic agents in treatment of some cancer diseases. Reasons ribozymes are considered; Detailed information on ribozymes.

  • Hyperthermia in the treatment of cancer. Shimm, David S.; Gerweck, Leo E.; Shimm, D S; Gerweck, L E // Annals of Internal Medicine;May84, Vol. 100 Issue 5, p757 

    Editorial. Discusses the use of hyperthermia in the treatment of cancer. History of the procedure; Conditions that alter response to hyperthermia; Information on the cytotoxicity of hyperthermia.

  • Tamoxifen: The herald of a new era of preventive therapeutics. Jordan, V. Craig // JNCI: Journal of the National Cancer Institute;06/04/97, Vol. 89 Issue 11, p747 

    Editorial. Focuses on the use of tamoxifen in the treatment of breast cancer. Data from clinical trials of tamoxifen as an anticancer agent; Use in cancer prevention; Side effects of tamoxifen.

  • Playing the old piano: another tune for endocrine therapy? Hayes, Daniel F. // JNCI: Journal of the National Cancer Institute;11/5/2003, Vol. 95 Issue 21, p1565 

    Editorial. Discusses endocrine treatment for breast cancer. Clinical conundrums generated by the use of endocrine therapy in the treatment of breast cancer; Importance of understanding the difference between hormone-independent cancers; Importance of understanding the biology of estrogen activity.

  • Prevention of colorectal cancer by endoscopic polypectomy. Van Dam, Jacques // Annals of Internal Medicine;12/15/95, Vol. 123 Issue 12, p949 

    Editorial. Presents an abstract on the prevention of colorectal cancer by endoscopic polypectomy. Colon cancer in the United States; Treating colon cancer; Endoscopic and polypectomy treatments against colon cancer.

  • Aberrant expression of retinoid receptors and lung carcinogenesis. Lotan, Reuben; Lotan, R // JNCI: Journal of the National Cancer Institute;06/16/99, Vol. 91 Issue 12, p989 

    Editorial. Focuses on lung cancer as the leading cause of cancer deaths in the United States for both women and men as of 1999. Treatments for cancer; Effectiveness of using retinoids for lung cancer prevention; How retinoids work.

  • Hobson's Choice and the Need for Combinations of New Agents for the Prevention and Treatment of Breast Cancer. Sporn, Michael B. // JNCI: Journal of the National Cancer Institute;2/20/2002, Vol. 94 Issue 4, p242 

    Editorial. Comments on the implication of Hobson's Choice for the prevention and treatment of breast cancer. Administration of tamoxifen and raloxifene for breast cancer; Mechanisms of action of rexinoids; Principles on the pharmacologic intervention to breast cancer.


Other Topics